Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | POLB | P06746 | 4/20 | 0.44 |
| ▸ | PKM | P14618 | 4/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28089140 | 0.80 | HCAR2 (0.51) | ALOX5KMT2APOLBPKML3MBTL1 | |
| SCHEMBL7108625 | 0.79 | NPC1 (0.44) | ALOX5KMT2APOLBPKML3MBTL1 | |
| SCHEMBL30322580 | 0.79 | ALOX5 (0.42) | ALOX5KMT2APOLBPKML3MBTL1 | |
| SCHEMBL28978362 | 0.78 | ALOX5 (0.46) | ALOX5KMT2APOLBPKML3MBTL1 | |
| SCHEMBL28978375 | 0.78 | ALOX5 (0.46) | ALOX5KMT2APOLBPKML3MBTL1 | |
| SCHEMBL28978371 | 0.78 | ALOX5 (0.46) | ALOX5KMT2APOLBPKML3MBTL1 | |
| SCHEMBL28978365 | 0.78 | ALOX5 (0.46) | ALOX5KMT2APOLBPKML3MBTL1 | |
| SCHEMBL11047695 | 0.77 | ALOX5 (0.41) | ALOX5KMT2APOLBPKML3MBTL1 | |
| SCHEMBL14073828 | 0.77 | ALOX5 (0.41) | ALOX5KMT2APOLBPKML3MBTL1 | |
| SCHEMBL27884913 | 0.77 | KMT2A (0.42) | ALOX5KMT2APOLBPKML3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2509949-B1 | PYRIDINONE HYDROXYCYCLOPENTYL CARBOXAMIDES: HIV INTEGRASE INHIBITORS WITH THERAPEUTIC APPLICATIONS | UNIV GEORGIA (US) | 2014-04-23 | — | — | EP | claimed |
| US-8703801-B2 | Pyridinone hydroxycyclopentyl carboxamides: HIV integrase inhibitors with therapeutic applications | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2014-04-22 | — | — | US | claimed |
| US-20120282218-A1 | PYRIDINONE HYDROXYCYCLOPENTYL CARBOXAMIDES: HIV INTEGRASE INHIBITORS WITH THERAPEUTIC APPLICATIONS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION INC. (US) | 2012-11-08 | — | — | US | claimed |
| EP-2509949-A2 | PYRIDINONE HYDROXYCYCLOPENTYL CARBOXAMIDES: HIV INTEGRASE INHIBITORS WITH THERAPEUTIC APPLICATIONS | University Of Georgia Research Foundation, Inc. (US) | 2012-10-17 | — | — | EP | claimed |
| WO-2011071849-A2 | PYRIDINONE HYDROXYCYCLOPENTYL CARBOXAMIDES: HIV INTEGRASE INHIBITORS WITH THERAPEUTIC APPLICATIONS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2011-06-16 | — | — | WO | claimed |
| CN-112704738-A | Methods of treating cancer and other disorders or disease states using clevudine and telbivudine | 耶鲁大学 | 2021-04-27 | — | — | CN | disclosed |
| EP-2298783-B1 | Anti-viral nucleoside analogs and methods for treating viral infections, especially hiv infections | UNIV YALE (US) | 2017-12-06 | — | — | EP | disclosed |
| CN-104254526-B | For new anti-mycobacteria medicine lungy | 乔治亚大学研究基金公司 | 2017-06-20 | — | — | CN | disclosed |
| US-9650360-B2 | Anti-mycobacterial drugs against tuberculosis | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2017-05-16 | — | — | US | disclosed |
| EP-2831056-B1 | NEW ANTI-MYCOBACTERIAL DRUGS AGAINST TUBERCULOSIS | THE UNIV OF GEORGIA RES FOUND INC (US) | 2016-12-14 | — | — | EP | disclosed |
| US-9126971-B2 | Anti-viral nucleoside analogs and methods for treating viral infections, especially HIV infections | YALE UNIVERSITY (US) | 2015-09-08 | — | — | US | disclosed |
| US-20150050237-A1 | NEW ANTI-MYCOBACTERIAL DRUGS AGAINST TUBERCULOSIS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-02-19 | — | — | US | disclosed |
| WO-2007106450-A2 | DIKETO ACIDS WITH NUCLEOBASE SCAFFOLDS: ANTI-HIV REPLICATION INHIBITORS TARGETED AT HIV INTEGRASE IN COMBINATION THERAPY | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2007-09-20 | — | — | WO | disclosed |
| WO-2007067364-A2 | METHODS OF TREATING CANCER AND OTHER CONDITIONS OR DISEASE STATES USING L-CYTOSINE NUCLEOSIDE ANALOGS | YALE UNIVERSITY (US) | 2007-06-14 | — | — | WO | disclosed |
| WO-2006133092-A1 | METHODS OF TREATING CANCER AND OTHER CONDITIONS OR DISEASE STATES USING LFMAU AND LDT | YALE UNIVERSITY (US) | 2006-12-14 | — | — | WO | disclosed |
| EP-1653976-A1 | ANTI-VIRAL NUCLEOSIDE ANALOGS AND METHODS FOR TREATING VIRAL INFECTIONS, ESPECIALLY HIV INFECTIONS | YALE UNIVERSITY (US) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005011709-A1 | ANTI-VIRAL NUCLEOSIDE ANALOGS AND METHODS FOR TREATING VIRAL INFECTIONS, ESPECIALLY HIV INFECTIONS | YALE UNIVERSITY (US) | 2005-02-10 | — | — | WO | disclosed |
| US-20040167096-A1 | Anti-viral nucleoside analogs and methods for treating viral infections, especially HIV infections | YALE UNIVERSITY | 2004-08-26 | — | — | US | disclosed |
| US-20040138153-A1 | Treatment of neurodegenerative diseases using proteasome modulators | ALS THERAPY DEVELOPMENT FOUNDATION | 2004-07-15 | — | — | US | disclosed |
| WO-2003101481-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES USING PROTEASOME MODULATORS | ALS THERAPY DEVELOPMENT FOUNDATION (US) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138153-A1 | Treatment of neurodegenerative diseases using proteasome modulators | PSME3, PSMD3, PSMC1 | ALOX5 3340/4885KMT2A 475/4885POLB 1473/4885 |
| US-20120282218-A1 | PYRIDINONE HYDROXYCYCLOPENTYL CARBOXAMIDES: HIV INTEGRASE INHIBITORS WITH THERAPEUTIC APPLICATIONS | PAICS, DUT, AADAC | ALOX5 1692/4885KMT2A 2438/4885POLB 324/4885 |
| US-20150050237-A1 | NEW ANTI-MYCOBACTERIAL DRUGS AGAINST TUBERCULOSIS | FNTB, ABCC1, TBCD | ALOX5 4472/4885KMT2A 3309/4885POLB 67/4885 |
| US-20040167096-A1 | Anti-viral nucleoside analogs and methods for treating viral infections, especially HIV infections | CCR1, CCR4, CCR3 | ALOX5 3133/4885KMT2A 4190/4885POLB 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.